Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.
Locoregional recurrence after radical surgery;
Positive resection margin (R1/R2) after surgery;
Out-of-field recurrence after adjuvant chemoradiation or radiotherapy;
Recurrence after adjuvant chemotherapy;
Age>70 or <16 years;
Pregnancy or lactation;
History of drug allergy;
Declining informed consent;
Chinese Academy of Medical Sciences
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborator
Tianjin Medical University Cancer Institute and Hospital
Collaborator
Anyang Tumor Hospital
Collaborator
Fujian Cancer Hospital
Collaborator
Peking University Cancer Hospital & Institute
Collaborator
Hebei Medical University Fourth Hospital
Collaborator